BTIG raises Tempus AI stock price target to $100 on data deals
BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.
How this was made
The 30-second read
Why it matters
The earnings beat and new contracts drove analyst upgrades and price‑target hikes, indicating near‑term upside.
Market read
Strong earnings and data‑deal pipeline could lift the broader health‑tech sector.
What to watch
Potential regulatory scrutiny of data partnerships and integration risks with large pharma partners.
Background
Tempus AI reported Q3 2026 results with revenue of $411.5M, adjusted EPS of $0.07 beating forecasts, and announced several high‑value data deals.
Ticker impact
BTIG raised its price target to $100 and highlighted Tempus AI's earnings beat, revenue growth and new data deals.
likely upward pressure as investors price in stronger guidance and data contracts
The company posted 50% revenue growth, beat EPS expectations and secured a $200M deal, prompting analysts to raise targets.
Market effects
Strengthens outlook for AI‑driven health‑data sector.
Boosts US biotech and data‑analytics stocks.
Highlights growing demand for oncology data platforms worldwide.
Counterpoint
Valuation may be stretched; price target of $100 could be optimistic given high growth expectations.
Key entities
- companyTempus AI Inc
AI‑driven oncology data platform.
- partnerBristol Myers Squibb
Pharma partner in a $200M data deal.
